Alexander I. Salter

Alexander I. Salter

Auto-generated profile, based on publicly available information

Alexander I. Salter

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2018 in Science Signaling
Verified
Journal Article
Closed access
PDF file
ASAlexander I. Salter
Alexander I. Salter
RIRichard G. Ivey
Richard G. Ivey
JKJacob J. Kennedy
Jacob J. Kennedy
VVValentin Voillet
Valentin Voillet
ARAnusha Rajan
Anusha Rajan
SRStanley R. Riddell
Stanley R. Riddell
Chimeric antigen receptors (CARs) link an antigen recognition domain to intracellular signaling domains to redirect T cell specificity and function. T cells expressing CARs with CD28/CD3ζ or 4-1BB/CD3ζ signaling domains are effective at treating refractory B cell malignancies but exhibit differences in effector function, clinical efficacy, and toxicity that are assumed to result from the activation of divergent signaling cascades. We analyzed stimulation-induced phosphorylation events in primary human CD8+ CD28/CD3ζ and 4-1BB/CD3ζ CAR T cells by mass spectrometry and found that both CAR constructs activated similar signaling intermediates. Stimulation of CD28/CD3ζ CARs activated faster and larger-magnitude changes in protein phosphorylation, which correlated with an effector T cell–like phenotype and function. In contrast, 4-1BB/CD3ζ CAR T cells preferentially expressed T cell memory–associated genes and exhibited sustained antitumor activity against established tumors in vivo. Mutagenesis of the CAR CD28 signaling domain demonstrated that the increased CD28/CD3ζ CAR signal intensity was partly related to constitutive association of Lck with this domain in CAR complexes. Our data show that CAR signaling pathways cannot be predicted solely by the domains used to construct the receptor and that signal strength is a key determinant of T cell fate. Thus, tailoring CAR design based on signal strength may lead to improved clinical efficacy and reduced toxicity.

20 March 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Roland Bruno WalterRoland Bruno Walter
Roland Bruno Walter
TGTed A. Gooley
Ted A. Gooley
BWBrent L. Wood
Brent L. Wood
FMFilippo Milano
Filippo Milano
MFMin Fang
Min Fang
JPJohn M. Pagel
John M. Pagel
Purpose: Allogeneic hematopoietic cell transplantation (HCT) benefits many patients with acute myeloid leukemia (AML) in first remission. Hitherto, little attention has been given to the prognostic impact of pretransplantation minimal residual disease (MRD). Patients and Methods: We retrospectively studied 99 consecutive patients receiving myeloablative HCT for AML in first morphologic remission. Ten-color multiparametric flow cytometry (MFC) was performed on bone marrow aspirates before HCT. MRD was identified as a cell population showing deviation from normal antigen expression patterns compared with normal or regenerating marrow. Any level of residual disease was considered MRD positive. Results: Before HCT, 88 patients met morphologic criteria for complete remission (CR), whereas 11 had CR with incomplete blood count recovery (CRi). Twenty-four had MRD before HCT as determined by MFC. Two-year estimates of overall survival were 30.2% (range, 13.1% to 49.3%) and 76.6% (range, 64.4% to 85.1%) for MRD-positive and MRD-negative patients; 2-year estimates of relapse were 64.9% (range, 42.0% to 80.6%) and 17.6% (range, 9.5% to 27.9%). After adjustment for all or a subset of cytogenetic risk, secondary disease, incomplete blood count recovery, and abnormal karyotype pre-HCT, MRD-positive HCT was associated with increased overall mortality (hazard ratio [HR], 4.05; 95% CI, 1.90 to 8.62; P < .001) and relapse (HR, 8.49; 95% CI, 3.67 to 19.65; P < .001) relative to MRD-negative HCT. Conclusion: These data suggest that pre-HCT MRD is associated with increased risk of relapse and death after myeloablative HCT for AML in first morphologic CR, even after controlling for other risk factors.

1 March 2019 in Cancer Cell
Verified
Journal Article
Closed access
SSShivani Srivastava
Shivani Srivastava
ASAlexander I. Salter
Alexander I. Salter
DLDenny Liggitt
Denny Liggitt
SYSushma Yechan-Gunja
Sushma Yechan-Gunja
MSMegha Sarvothama
Megha Sarvothama
SRStanley R. Riddell
Stanley R. Riddell

25 September 2019 in Blood
Verified
Journal Article
Closed access
PDF file
MPMargot J. Pont
Margot J. Pont
THTyler Hill
Tyler Hill
GCGabriel O. Cole
Gabriel O. Cole
JAJoe J. Abbott
Joe J. Abbott
JKJessica Kelliher
Jessica Kelliher
SRStanley R. Riddell
Stanley R. Riddell
B cell maturation antigen (BCMA) is a validated target for chimeric antigen receptor (CAR) T cell therapy in multiple myeloma (MM). Despite promising objective response rates, most patients relapse and low levels of BCMA on a subset of tumor cells has been suggested as a probable escape mechanism. BCMA is actively cleaved from the tumor cell surface by the ubiquitous multisubunit γ-secretase complex, which reduces ligand density on tumor cells for CAR-T cell recognition and releases a soluble BCMA (sBCMA) fragment capable of inhibiting CAR-T cell function. Sufficient sBCMA can accumulate in the bone marrow of MM patients to inhibit CAR-T cell recognition of tumor cells, and potentially limit efficacy of BCMA directed adoptive T cell therapy. We investigated whether blocking BCMA cleavage by small molecule γ-secretase inhibitors (GSIs) could augment BCMA-targeted CAR-T cell therapy. We found that exposure of myeloma cell lines and patient tumor samples to GSIs markedly increased surface BCMA levels in a dose-dependent fashion, concurrently decreased sBCMA concentrations, and improved tumor recognition by CAR-T cells in vitro. GSI treatment of MM tumor bearing NOD/SCID/γc-/- mice increased BCMA expression on tumor cells, decreased sBCMA in peripheral blood, and improved antitumor efficacy of BCMA-targeted CAR-T cell therapy. Importantly, short term GSI administration to MM patients markedly increases the percentage of BCMA+tumor cells, and the levels of BCMA surface expression in vivo. Based on these data, an FDA-approved clinical trial (NCT03502577) has been initiated, combining GSI with concurrent BCMA CAR-T cell therapy. Key Points Small molecule γ-secretase inhibitors increase BCMA surface expression on myeloma cells, resulting in enhanced CAR-T cell efficacy.

25 September 2020 in Science
Verified
Journal Article
Closed access
MLMarc J. Lajoie
Marc J. Lajoie
SBScott E. Boyken
Scott E. Boyken
ASAlexander I. Salter
Alexander I. Salter
JBJilliane Bruffey
Jilliane Bruffey
ARAnusha Rajan
Anusha Rajan
DBDavid Baker
David Baker
Logic at the cell surface: A major challenge in medical interventions is to target only diseased cells. Although there are biomarkers characteristic of certain cancers, for example, it is unlikely that a single marker can specify a particular cell type. Lajoie et al. addressed this problem by designing protein switches called Co-LOCKR that bind to antigens on the cell surface and activate through a conformational change only when there is a precise combination of antigens. They designed switches that can perform AND, OR, and NOT logic. On the path toward applying this technology, they used Co-LOCKR to direct chimeric antigen receptor T cells to tumor cells expressing specific antigens. Science , this issue p. 1637

16 February 2017 in Leukemia
Verified
Journal Article
Open access
PDF file
DSD Sommermeyer
D Sommermeyer
THT Hill
T Hill
SSS M Shamah
S M Shamah
ASA I Salter
A I Salter
YCY Chen
Y Chen
SRS R Riddell
S R Riddell
Impressive results have been achieved by adoptively transferring T-cells expressing CD19-specific CARs with binding domains from murine mAbs to treat B-cell malignancies. T-cell mediated immune responses specific for peptides from the murine scFv antigen-binding domain of the CAR can develop in patients and result in premature elimination of CAR T-cells increasing the risk of tumor relapse. As fully human scFv might reduce immunogenicity, we generated CD19-specific human scFvs with similar binding characteristics as the murine FMC63-derived scFv using human Ab/DNA libraries. CARs were constructed in various formats from several scFvs and used to transduce primary human T-cells. The resulting CD19-CAR T-cells were specifically activated by CD19-positive tumor cell lines and primary chronic lymphocytic leukemia cells, and eliminated human lymphoma xenografts in immunodeficient mice. Certain fully human CAR constructs were superior to the FMC63-CAR, which is widely used in clinical trials. Imaging of cell surface distribution of the human CARs revealed no evidence of clustering without target cell engagement, and tonic signaling was not observed. To further reduce potential immunogenicity of the CARs, we also modified the fusion sites between different CAR components. The described fully human CARs for a validated clinical target may reduce immune rejection compared with murine-based CARs.